Bio-Techne Statistics
Total Valuation
Bio-Techne has a market cap or net worth of $8.39 billion. The enterprise value is $8.56 billion.
| Market Cap | 8.39B |
| Enterprise Value | 8.56B |
Important Dates
The last earnings date was Wednesday, February 4, 2026, before market open.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Feb 13, 2026 |
Share Statistics
Bio-Techne has 156.45 million shares outstanding. The number of shares has decreased by -2.20% in one year.
| Current Share Class | 156.45M |
| Shares Outstanding | 156.45M |
| Shares Change (YoY) | -2.20% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | 1.12% |
| Owned by Institutions (%) | 111.99% |
| Float | 154.58M |
Valuation Ratios
The trailing PE ratio is 103.26 and the forward PE ratio is 26.03. Bio-Techne's PEG ratio is 2.52.
| PE Ratio | 103.26 |
| Forward PE | 26.03 |
| PS Ratio | 6.90 |
| Forward PS | 6.55 |
| PB Ratio | 4.16 |
| P/TBV Ratio | 12.06 |
| P/FCF Ratio | 37.62 |
| P/OCF Ratio | 33.65 |
| PEG Ratio | 2.52 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 25.90, with an EV/FCF ratio of 38.38.
| EV / Earnings | 105.61 |
| EV / Sales | 7.04 |
| EV / EBITDA | 25.90 |
| EV / EBIT | 31.61 |
| EV / FCF | 38.38 |
Financial Position
The company has a current ratio of 4.54, with a Debt / Equity ratio of 0.17.
| Current Ratio | 4.54 |
| Quick Ratio | 2.59 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 0.99 |
| Debt / FCF | 1.57 |
| Interest Coverage | 29.15 |
Financial Efficiency
Return on equity (ROE) is 3.97% and return on invested capital (ROIC) is 8.75%.
| Return on Equity (ROE) | 3.97% |
| Return on Assets (ROA) | 6.52% |
| Return on Invested Capital (ROIC) | 8.75% |
| Return on Capital Employed (ROCE) | 11.37% |
| Weighted Average Cost of Capital (WACC) | 11.94% |
| Revenue Per Employee | $392,122 |
| Profits Per Employee | $26,148 |
| Employee Count | 3,100 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 2.06 |
Taxes
In the past 12 months, Bio-Techne has paid $33.09 million in taxes.
| Income Tax | 33.09M |
| Effective Tax Rate | 28.98% |
Stock Price Statistics
The stock price has decreased by -14.75% in the last 52 weeks. The beta is 1.47, so Bio-Techne's price volatility has been higher than the market average.
| Beta (5Y) | 1.47 |
| 52-Week Price Change | -14.75% |
| 50-Day Moving Average | 62.35 |
| 200-Day Moving Average | 57.52 |
| Relative Strength Index (RSI) | 35.70 |
| Average Volume (20 Days) | 2,461,641 |
Short Selling Information
The latest short interest is 11.31 million, so 7.23% of the outstanding shares have been sold short.
| Short Interest | 11.31M |
| Short Previous Month | 9.84M |
| Short % of Shares Out | 7.23% |
| Short % of Float | 7.32% |
| Short Ratio (days to cover) | 4.18 |
Income Statement
In the last 12 months, Bio-Techne had revenue of $1.22 billion and earned $81.06 million in profits. Earnings per share was $0.52.
| Revenue | 1.22B |
| Gross Profit | 809.63M |
| Operating Income | 270.81M |
| Pretax Income | 114.19M |
| Net Income | 81.06M |
| EBITDA | 330.54M |
| EBIT | 270.81M |
| Earnings Per Share (EPS) | $0.52 |
Balance Sheet
The company has $179.55 million in cash and $350.90 million in debt, with a net cash position of -$171.35 million or -$1.10 per share.
| Cash & Cash Equivalents | 179.55M |
| Total Debt | 350.90M |
| Net Cash | -171.35M |
| Net Cash Per Share | -$1.10 |
| Equity (Book Value) | 2.01B |
| Book Value Per Share | 12.90 |
| Working Capital | 497.01M |
Cash Flow
In the last 12 months, operating cash flow was $249.32 million and capital expenditures -$26.30 million, giving a free cash flow of $223.02 million.
| Operating Cash Flow | 249.32M |
| Capital Expenditures | -26.30M |
| Free Cash Flow | 223.02M |
| FCF Per Share | $1.43 |
Margins
Gross margin is 66.60%, with operating and profit margins of 22.28% and 6.67%.
| Gross Margin | 66.60% |
| Operating Margin | 22.28% |
| Pretax Margin | 9.39% |
| Profit Margin | 6.67% |
| EBITDA Margin | 27.19% |
| EBIT Margin | 22.28% |
| FCF Margin | 18.35% |
Dividends & Yields
This stock pays an annual dividend of $0.32, which amounts to a dividend yield of 0.61%.
| Dividend Per Share | $0.32 |
| Dividend Yield | 0.61% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 61.63% |
| Buyback Yield | 2.20% |
| Shareholder Yield | 2.79% |
| Earnings Yield | 0.97% |
| FCF Yield | 2.66% |
Analyst Forecast
The average price target for Bio-Techne is $73.09, which is 36.31% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $73.09 |
| Price Target Difference | 36.31% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 7.48% |
| EPS Growth Forecast (5Y) | 44.69% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 30, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Nov 30, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
Bio-Techne has an Altman Z-Score of 12.36 and a Piotroski F-Score of 8.
| Altman Z-Score | 12.36 |
| Piotroski F-Score | 8 |